Targeting the checkpoint kinases: chemosensitization versus chemoprotection.
Zhou
Bin-Bing S
BB
Drug Discovery Biology, Incyte Corporation, Experimental Station, Rt. 141 & Henry Clay Road, Bldg 400, Wilmington, DE 19880, USA. bzhou@incyte.com
Bartek
Jiri
J
D016588:Anticarcinogenic Agents / Q000145:classification / Q000627:therapeutic use* / Q000633:toxicity; D000970:Antineoplastic Agents / Q000145:classification / Q000627:therapeutic use* / Q000633:toxicity; D064447:Checkpoint Kinase 2; D004249:DNA Damage / Q000235:genetics; D016147:Genes, Tumor Suppressor; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000517:prevention & control*; D011494:Protein Kinases / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism
D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D011494:Protein Kinases; D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases